Her2 and Progesterone Receptor Status Are Not Predictive of Response to Fulvestrant Treatment

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-3050
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance Between Immuno-Histochemistry and MapQuant™ Microarray Based Assay

PLoS ONE
Multidisciplinary
2016English

Cyclin D1 Enhances the Response to Estrogen and Progesterone by Regulating Progesterone Receptor Expression

Molecular and Cellular Biology
Cell BiologyMolecular Biology
2010English

Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?

Therapeutic Advances in Medical Oncology
Oncology
2018English

Androgen Receptor Status Predicts Response to Chemotherapy, Not Risk of Breast Cancer in Indian Women

World Journal of Surgical Oncology
SurgeryOncology
2010English

Author Response To: Comment On: Meta-Analysis of the Impact of Progesterone Receptor Status on Oncological Outcomes in Oestrogen Receptor-Positive Breast Cancer

British Journal of Surgery
Surgery
2020English

All HER2-Positive Tumors Are Not Created Equal

Annals of Surgical Oncology
OncologySurgery
2017English

Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Estrogen Receptor, Progesterone Receptor, and HER2-neu Expression in First Primary Breast Cancers and Risk of Second Primary Contralateral Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Five Interpersonal Factors Are Predictive of the Response to Treatment of Major Depression With Antidepressants in Primary Care

Frontiers in Psychiatry
PsychiatryMental Health
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy